AFFILIATIONS
1 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
2 Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
3 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States
4 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
5 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
6 Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
7 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
8 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
9 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States
10 Department of Computational and Quantitative Medicine, Beckman Research Institute of City of Hope, Duarte, California, United States
11 Department of Pathology, City of Hope, Duarte, California, United States
12 Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
13 Fred Hutchinson Cancer Center, Seattle, Washington, United States
14 Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
15 Author D. Riggs Diabetes and Metabolism Research Institute, The Beckman Research Institute of City of Hope, Duarte, California, United States, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, California, United States
ABSTRACT
Background: Sebaceous glands (SGs) and tissue-resident memory T (Trm) cells in the skin play important roles in host defense against infection and in maintaining skin homeostasis. Cutaneous GVHD (cGVHD) is common in patients after hematopoietic stem cell transplantation (HSCT), causing hair follicle damage and dermal fibrosis. However, the contributions of Trm cell disruption and SG damage to cGVHD pathogenesis remain poorly understood.
Methods. We used murine cGVHD models with or without post-transplant cyclophosphamide (PTCy), donor T cells genetically deficient in T-bet or BATF, and humanized NSG-MHCKO HLA-A2/DR4 recipients, together with antibody-mediated depletion (anti-CD4, anti-CD103). Skin-infiltrating immune cells were analyzed by flow cytometry, Xenium spatial transcriptomics, histology and immunofluorescence.
Results. In cGVHD, skin CD103⁺CD4⁺ Trm cells were skewed toward a pathogenic Foxp3⁻ effector program, rather than the Foxp3⁺ regulatory (Treg) program of No-GVHD recipients. In the No-GVHD controls (bone marrow alone), skin CD103⁺CD4⁺ tissue-resident Tregs showed a stem/progenitor-like phenotype (Ly108⁺TCF1⁺) and represented ~37% of donor CD4⁺ T cells; in cGVHD skin, this Foxp3⁺ regulatory fraction collapsed to ~1%, and the CD103⁺ compartment was instead dominated by terminally differentiated effectors co-producing IFN-γ, GM-CSF and TNF-α. T-bet–deficient donor T cells preserved the CD103⁺Foxp3⁺ fraction; consistently, CD4 depletion, recipient MHC class II deficiency, and donor T cell specific BATF or T-bet deficiency each prevented pathogenic CD103+ Trm accumulation and SG damage. In a humanized xenograft cGVHD model, human donor T cells differentiated into pathogenic CD103⁺ Trm, driving SG injury and severe cutaneous GVHD, recapitulating the murine phenotype. Xenium spatial analysis showed that pathogenic CD103⁺ Trm localized adjacent to SG progenitors which acquired an interferon-stimulated, senescent program, with downregulation of lineage-commitment and sebocyte-differentiation genes (Cidea, Srebf1, Scd1). Importantly, therapeutic intervention after cGVHD onset with inducible donor T-cell Tgfbr2 deletion or anti-CD103 depletion reduced pathogenic CD103⁺ Trm, restored SG integrity, and attenuated cGVHD. The senolytic combination dasatinib plus quercetin (D+Q) restored SG progenitor abundance and reduced cGVHD pathogenesis.
Conclusions. cGVHD disrupts CD103+CD4+ Trm-mediated tissue-resident immune tolerance in a T-bet–dependent manner, driving SG progenitor senescence and exacerbating cGVHD. Our findings establish tissue-resident immune tolerance as a key regulator of epithelial progenitor integrity and identify pathogenic CD103⁺ Trm and SG progenitor senescence as therapeutic targets in cGVHD.